Search research articles
Contact Us
Filters
Showing results (21-30 of 39) with videos related to
Page
of 4
Sort By:
Cancer
|
September 16, 2003
Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma
Eunice S Wang, David J Straus, Julie Teruya-Feldstein, et al.
Leukemia & Lymphoma
|
January 16, 2023
Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with <i>CREBBP</i> or <i>EP300</i> mutations: an open label phase II study
David Qualls, Ariela Noy, David Straus, et al.
British Journal of Haematology
|
June 8, 2004
Adverse prognostic significance of CD20 positive Reed-Sternberg cells in classical Hodgkin's disease
Carol S Portlock, Gerard B Donnelly, Jing Qin, et al.
JAMA Network Open
|
June 21, 2023
Factors Associated With Unmet Supportive Care Needs and Emergency Department Visits and Hospitalizations in Ambulatory Oncology
Frank J Penedo, Akina Natori, Sara E Fleszar-Pavlovic, et al.
Haematologica
|
April 2, 2019
Clinical presentation determines selection of patients for initial observation in mantle cell lymphoma
Anita Kumar, Zhitao Ying, Anna Alperovich, et al.
Leukemia & Lymphoma
|
April 24, 2019
Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma
Bastian von Tresckow, Michelle Fanale, Kirit M Ardeshna, et al.
Leukemia & Lymphoma
|
March 20, 2026
Predictors and timing of venous thromboembolism and overall survival in lymphoma
Asaad Trabolsi, Thomas E Plate, Tessa Lavorgna, et al.
Leukemia & Lymphoma
|
August 16, 2022
Bendamustine in combination with ofatumumab as first line treatment for elderly patients with mantle cell lymphoma: a phase II risk-adapted design
Anita Kumar, Carla Casulo, Erel Joffe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 23, 2004
Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma
Owen A O'Connor, John Wright, Craig Moskowitz, et al.
British Journal of Haematology
|
July 24, 2009
Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma
John Gerecitano, Carol Portlock, Craig Moskowitz, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 39) with videos related to
Sort By:
Page
of 4
Cancer
|
September 16, 2003
Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma
Eunice S Wang, David J Straus, Julie Teruya-Feldstein, et al.
Leukemia & Lymphoma
|
January 16, 2023
Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with <i>CREBBP</i> or <i>EP300</i> mutations: an open label phase II study
David Qualls, Ariela Noy, David Straus, et al.
British Journal of Haematology
|
June 8, 2004
Adverse prognostic significance of CD20 positive Reed-Sternberg cells in classical Hodgkin's disease
Carol S Portlock, Gerard B Donnelly, Jing Qin, et al.
JAMA Network Open
|
June 21, 2023
Factors Associated With Unmet Supportive Care Needs and Emergency Department Visits and Hospitalizations in Ambulatory Oncology
Frank J Penedo, Akina Natori, Sara E Fleszar-Pavlovic, et al.
Haematologica
|
April 2, 2019
Clinical presentation determines selection of patients for initial observation in mantle cell lymphoma
Anita Kumar, Zhitao Ying, Anna Alperovich, et al.
Leukemia & Lymphoma
|
April 24, 2019
Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma
Bastian von Tresckow, Michelle Fanale, Kirit M Ardeshna, et al.
Leukemia & Lymphoma
|
March 20, 2026
Predictors and timing of venous thromboembolism and overall survival in lymphoma
Asaad Trabolsi, Thomas E Plate, Tessa Lavorgna, et al.
Leukemia & Lymphoma
|
August 16, 2022
Bendamustine in combination with ofatumumab as first line treatment for elderly patients with mantle cell lymphoma: a phase II risk-adapted design
Anita Kumar, Carla Casulo, Erel Joffe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 23, 2004
Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma
Owen A O'Connor, John Wright, Craig Moskowitz, et al.
British Journal of Haematology
|
July 24, 2009
Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma
John Gerecitano, Carol Portlock, Craig Moskowitz, et al.
Page
of 4